Fieldpoint Private Securities’s Genmab GMAB Stock Holding History

Fieldpoint Private Securities’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Sell	30 -385	-93%	-$12.5K	﹤0.01%	1340
2022 Q1	$15K	Hold	415	–	–	﹤0.01%	940
2021 Q4	$16K	Hold	415	–	–	﹤0.01%	937
2021 Q3	$18K	Buy	415 +105	+34%	+$4.71K	﹤0.01%	848
2021 Q2	$14K	Hold	310	–	–	﹤0.01%	920
2021 Q1	$10K	Hold	310	–	–	﹤0.01%	1000
2020 Q4	$13K	Buy	+310	New	+$11.6K	﹤0.01%	818

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fieldpoint Private Securities's GMAB Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Genmab (GMAB) stake by 93% in Q2 2022, selling an estimated $12.5K and leaving 30 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Fieldpoint Private Securities first reported a position in GMAB in Q4 2020 and has held it in 7 quarters since. The position peaked at $18K in Q3 2021. 180 funds tracked by Wall St. Rank hold GMAB as of Q2 2022.

Fieldpoint Private Securities held 30 shares of Genmab worth $1K as of Q2 2022.
Fieldpoint Private Securities sold 385 Genmab shares in Q2 2022, an estimated $12.5K.
Genmab made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1340 holding.
Fieldpoint Private Securities first reported a position in Genmab in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Genmab position peaked at $18K in Q3 2021.
180 funds tracked by Wall St. Rank held Genmab as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.